This trial studies the best time point of using F18-FDG that gives the best image on PET-MRI in patients with spinal cord lesions of unknown cause. Diagnostic procedures, such as F18-FDG PET-MRI, may help find and diagnose spinal cord lesions.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04219969.
PRIMARY OBJECTIVES:
I. To identify the optimal imaging time point using fludeoxyglucose F-18 (F18-FDG) positron emission tomography (PET) that gives the best lesion conspicuity as defined by the best lesion to background (L/B) ratio when evaluating spinal cord lesions of unknown etiology.
EXPLORATORY OBJECTIVES:
I. To identify malignancy specific factors in F18-FDG metabolism derived from metrics such as maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), total lesion glycolysis (TLG), metabolic tumor volume (MTV) and L/B ratio.
OUTLINE:
Patients receive fludeoxyglucose F-18 intravenously (IV) over 1 minutes and then undergo PET-magnetic resonance imaging (MRI) over 15-60 minutes at 60, 300, and 480 minutes after fludeoxyglucose F-18 injection in the absence of unacceptable toxicity.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationM D Anderson Cancer Center
Principal InvestigatorMaria K Gule-Monroe
